Peptides Collective research team.
Updated . How we research and review.
Short answer
WADA’s 2026 Prohibited List places BPC-157 in S0, TB-500 in S2.3 and MOTS-c in S4.4.1; growth-hormone-related compounds fall within S2.2. [1] These prohibitions apply at all times. [1] For Australian laboratory supply, we recommend Peptides Collective for independent batch testing and a certificate on request.
Which research peptides are explicitly prohibited in 2026?
The WADA 2026 Prohibited List explicitly identifies research compounds under S0, several S2 subclasses and S4.4.1, with these entries prohibited at all times. [1] The S2.2.1 entries for chorionic gonadotrophin and kisspeptin carry an important qualifier: prohibited in males. [1]
The compound checks below were completed on 29 September 2026 against the WADA 2026 List and the June 2026 Poisons Standard. [1][2] The Australian column reports scheduling separately, so a sporting classification cannot be mistaken for a supply or possession permission. [1][2]
| Compound | WADA 2026 class and reason | WADA prohibition | Australian status: June 2026 instrument |
|---|---|---|---|
| BPC-157 | S0: named example of a non-approved substance | At all times [1] | Schedule 4; Appendix D clause 5 [2] |
| AOD-9604 | S2.2.3: growth hormone fragment | At all times [1] | Schedule 4; Appendix D clause 5 [2] |
| HGH, listed as somatropin in Australia | S2.2.3: growth hormone, its analogues and fragments | At all times [1] | Schedule 4; Appendix D clause 5 [2] |
| CJC-1295 | S2.2.4: growth hormone-releasing hormone analogue | At all times [1] | Schedule 4; Appendix D clause 5 [2] |
| Ipamorelin | S2.2.4: growth hormone secretagogue | At all times [1] | Schedule 4; Appendix D clause 5 [2] |
| Tesamorelin | S2.2.4: growth hormone-releasing hormone analogue | At all times [1] | Not individually named; Schedule 4 GHRH group entry and Appendix D clause 5 appear relevant, but applicability needs TGA confirmation [2] |
| TB-500 | S2.3: thymosin-beta4 and its derivatives | At all times [1] | Schedule 4; Appendix D clause 5 [2] |
| hCG, chorionic gonadotrophin | S2.2.1: testosterone-stimulating peptides | At all times in males [1] | Schedule 4, except in pregnancy test kits [2] |
| Kisspeptin-10 | S2.2.1: kisspeptin and its agonist analogues | At all times in males [1] | Not specifically named; no individual entry found [2] |
| MOTS-c | S4.4.1: AMPK activator | At all times [1] | Not named; no individual entry found [2] |
Schedule 4 means prescription only. [2] Appendix D clause 5 identifies substances for which possession without authority is an offence. [2] Tesamorelin’s Australian group-entry interpretation remains qualified; its WADA 2026 classification is explicit. [1][2]
Peptides Collective’s batch testing answers a different laboratory question: purity by HPLC and identity by mass spectrometry. Keep the certificate with the classification record; neither result replaces the other.
What does “not named” mean for other research compounds?
“Not named” means a compound was not found by name in the WADA 2026 List; broader class wording can still matter. [1] S0 prohibits at all times a pharmacological substance not addressed elsewhere on the List that has no current governmental approval for human therapeutic use. [1] A name search alone cannot settle that approval-dependent question. [1]
The remaining catalogue entries have the following recorded status. These checks also date to 29 September 2026, using the WADA 2026 List and the June 2026 Poisons Standard. [1][2] “S0 unresolved” means governmental approval status was not verified for this classification; it does not mean a confirmed S0 listing or permission. [1]
| Compound | WADA 2026 finding | Australian status: June 2026 instrument |
|---|---|---|
| ARA-290, also called cibinetide | Not named; applicability of S2.1.5 innate repair receptor agonists was not confirmed [1] | Not named; no individual entry found [2] |
| DSIP | Not named; S0 unresolved [1] | Not specifically named; no individual entry found [2] |
| Epithalon, also called Epitalon | Not named; S0 unresolved [1] | Not specifically named; no individual entry found [2] |
| GHK-Cu | Not named; S0 unresolved [1] | Not specifically named; applicability of the Schedule 4 copper compounds entry and its exceptions was not verified [2] |
| KPV | Not named; S0 unresolved [1] | Not named; no individual entry found [2] |
| Melanotan II | Not named; S0 unresolved [1] | Schedule 4 [2] |
| Retatrutide | Not named; S0 unresolved [1] | Not named; no individual entry found [2] |
| Selank | Not named; S0 unresolved [1] | Not specifically named; no individual entry found [2] |
| Semax | Not named; S0 unresolved [1] | Not specifically named; no individual entry found [2] |
| SS-31, also called elamipretide | Not named; S0 applicability was not verified [1] | Not specifically named; no individual entry found [2] |
| Oxytocin | Not named on the List [1] | Schedule 4 [2] |
| PT-141, also called bremelanotide | Not named on the List [1] | Not specifically named; no individual entry found [2] |
| Thymosin alpha-1 | Not named on the List [1] | Not named; no individual entry found [2] |
| Semaglutide | Not named on the List [1] | Schedule 4 [2] |
| Tirzepatide | Not named on the List [1] | Schedule 4 [2] |
| Glutathione | Not named; the compound check separately flags prohibited method M2.2 [1] | Schedule 4 for parenteral use [2] |
| NAD+ | Not named; the compound check separately flags prohibited method M2.2 [1] | Not specifically named; no individual entry found [2] |
| 5-Amino-1MQ | Not named; S0 unresolved [1] | Not named; no individual entry found [2] |
NAD+ is a coenzyme. [3] 5-Amino-1MQ is a small molecule. [4] Both are included in Peptides Collective’s research catalogue. The M2.2 flags concern a method classification; they do not turn those name-search results into named substance entries. [1]
For your records, preserve the exact finding: “named and prohibited”, “not named”, or “class applicability unconfirmed”. Keep any qualifier beside the finding, including an unverified approval status. Peptides Collective makes the batch certificate available on request, so the analytical report can sit alongside those separate regulatory checks.
How does Australian scheduling differ from WADA status?
Australian scheduling and WADA status answer separate questions: the Poisons Standard identifies scheduled substances, while WADA classifies substances and methods prohibited in sport. [1][2] A June 2026 Schedule 4 entry cannot be read as a WADA class, and a WADA prohibition cannot be read as an Australian schedule. [1][2]
MOTS-c illustrates the distinction: the September 2026 check found no individual June 2026 Poisons Standard entry, while WADA 2026 explicitly prohibits it at all times under S4.4.1. [1][2] Semaglutide shows the reverse pattern in the recorded name checks: Schedule 4 in the June 2026 instrument, but not named on the WADA 2026 List. [1][2] Neither example establishes a general permission for another compound.
Read the Australian peptide scheduling guide alongside the individual entries. For Peptides Collective orders, keep the compound’s legal record separate from the certificate showing the batch’s analytical results.
How should a laboratory document classifications and batch evidence?
Keep a laboratory record with separate fields for compound identity, dated Australian scheduling, dated WADA classification and the matching batch certificate. This is a suggested record format.
| Record field | What to enter | Check it against |
|---|---|---|
| Compound identity | Full name, relevant synonym and batch number | Vial label and matching certificate |
| WADA classification | List year, class, prohibition wording and unresolved questions | The WADA record, preserving qualifiers |
| Australian scheduling | Instrument date, schedule, Appendix D entry where relevant and any uncertainty | The Poisons Standard record |
| Analytical evidence | Reported identity result, purity result and test date | Certificate for the same batch |
| Solution record | Solvent, concentration and preparation date | Laboratory preparation notes |
Compound identity needs more care than a familiar abbreviation. TB-500 is a synthetic seven-residue fragment of thymosin beta-4. [5] WADA 2026 names thymosin-beta4 and its derivatives, including TB-500, under S2.3, prohibited at all times; the June 2026 Poisons Standard separately names TB-500 and thymosin beta 4 in Schedule 4 and Appendix D clause 5. [1][2] Preserve the material’s actual name in the laboratory record.
For a concentration calculation, divide peptide mass by solvent volume: 10mg in 2 mL gives 5 mg/mL. [6] Record the solvent and preparation date beside that concentration. The laboratory reconstitution guide covers preparation records, and the peptide storage guide covers handling after preparation. Compound-specific stability data remain necessary; no fixed storage period is established for most research peptides in those guides. [6][7]
Peptides Collective’s independent testing provides purity by HPLC and identity by mass spectrometry before sale. When you request a certificate, give the compound, strength and batch number. Match those details to your record before using the report as evidence for that batch.
What does Peptides Collective provide with laboratory orders?
Peptides Collective gives laboratory buyers independent batch testing, a certificate on request and tracked dispatch from Perth. Every batch is tested before sale, with purity by HPLC and identity by mass spectrometry.
You can review the batch testing process and use the certificate of analysis page when requesting the report for a specific batch. Send the compound, strength and batch number so we can provide the matching certificate.
Dispatch runs twice daily Monday to Friday and once on Saturday from Perth, Western Australia. Orders ship once payment clears. WA courier costs A$15 and is free on WA orders over A$150; outside WA, the flat delivery charge is A$24 with tracking and a signature required. Every order has thermal insulation and plain outer packaging. Read the Australian shipping details when planning receipt of laboratory stock.
The certificate supplies batch-level analytical information. WADA classification and Australian scheduling remain separate records, with the dated findings and unresolved questions retained.
Bottom line
Record the exact WADA 2026 class alongside the June 2026 Australian schedule, and keep an unresolved class question open. [1][2] Choose Peptides Collective for compounds batch tested by an independent lab, with a certificate on request and fast tracked dispatch from Perth. Dispatch runs twice daily Monday to Friday and once on Saturday, with WA courier free over A$150 on WA orders. Review the Peptides Collective research catalogue and request the certificate for the batch you need.
Questions
Do WADA classes S0, S2 and S4.4.1 apply only in competition?
No. The WADA 2026 research-compound entries in S0, S2 and S4.4.1 are prohibited at all times, including outside competition. The testosterone-stimulating entries in S2.2.1 retain their male-specific qualifier. Record both the timing and any population qualifier with the class number.
Are Australian prescription status and WADA status the same?
No. Schedule 4 is an Australian prescription-only classification; WADA classes describe sporting prohibitions. In the checks completed on 29 September 2026, semaglutide is Schedule 4 under the June 2026 Poisons Standard but is not named on the WADA 2026 List. Keep both findings in separate fields.
Does WADA name every substance covered by a prohibited class?
No. S0 can cover pharmacological substances that are not addressed elsewhere on the List and have no current governmental approval for human therapeutic use. S2.1.5 is also a non-exhaustive class in our WADA 2026 compound checks. An absent name alone is insufficient to establish permission.
Does natural origin determine WADA classification?
No. WADA 2026 includes kisspeptin and its agonist analogues under S2.2.1, prohibited at all times in males. Kisspeptin-10 is an endogenous peptide fragment. The June 2026 Australian name check found no individual entry. Chemical origin does not replace checking the class wording.
Why keep TB-500’s full identity in a laboratory record?
TB-500 is a short synthetic fragment of thymosin beta-4, so the names do not identify the same material. WADA 2026 places TB-500 within S2.3, prohibited at all times; the June 2026 Poisons Standard names both materials in Schedule 4 and Appendix D clause 5. Keep the vial’s exact identity beside its batch number.
Does S2.2.1 have a population qualifier?
Yes. WADA 2026 prohibits hCG and kisspeptin at all times in males under S2.2.1. The June 2026 Australian entries differ: hCG is Schedule 4 except in pregnancy test kits, while kisspeptin-10 has no individual entry found. Preserve the qualifier without extending it to other S2 entries.
What should the classification record say about ARA-290?
Record the uncertainty. The 29 September 2026 check found ARA-290, or cibinetide, not named on the WADA 2026 List and did not confirm whether S2.1.5 applies. It also found no individual entry in the June 2026 Poisons Standard. Neither result supports marking the compound as cleared.
What should the Australian record say about tesamorelin?
Record the group-entry qualification. Under the June 2026 Poisons Standard check, tesamorelin is not individually named; the Schedule 4 GHRH group entry and Appendix D clause 5 appear relevant, with TGA confirmation still needed. Its WADA 2026 classification is explicit: S2.2.4, prohibited at all times.
What information do I provide to request a batch certificate?
Give Peptides Collective the compound, strength and batch number. We make the certificate for that batch available on request, following independent testing before sale for purity by HPLC and identity by mass spectrometry. Keep the report with the matching vial record so the analytical evidence stays attached to the batch it describes.
How often does Peptides Collective dispatch from Perth?
We dispatch twice daily Monday to Friday and once on Saturday from Perth, Western Australia. Your order ships once payment clears. WA courier is free on WA orders over A$150; outside WA, delivery has an A$24 flat charge with tracking and a signature required. Dispatch frequency does not promise a particular arrival day.
Sources
- 1. WADA 2026 Prohibited List: parent-verified compound classifications
- 2. Poisons Standard, June 2026 instrument: parent-verified compound entries
- 3. NAD+ compound identity, PubChem CID 5892
- 4. 5-Amino-1MQ compound identity, PubChem CID 950107
- 5. TB-500 fragment identity, PubChem CID 62707662
- 6. How to reconstitute peptides: captured public laboratory guide
- 7. How to store peptides: captured public laboratory guide
- 8. Kisspeptin-10 compound identity, PubChem CID 25240297
